|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AIM1 |
Gene summary for AIM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AIM1 | Gene ID | 9212 |
| Gene name | aurora kinase B | |
| Gene Alias | AIK2 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000022 | UniProtAcc | Q96GD4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9212 | AIM1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.29e-72 | 1.30e+00 | 0.294 |
| 9212 | AIM1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.60e-16 | 1.29e+00 | 0.3487 |
| 9212 | AIM1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.91e-54 | 1.92e+00 | 0.281 |
| 9212 | AIM1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.54e-31 | 6.60e-01 | 0.3859 |
| 9212 | AIM1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.78e-27 | 8.17e-01 | 0.2585 |
| 9212 | AIM1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.28e-34 | 6.47e-01 | 0.3005 |
| 9212 | AIM1 | P1T-E | Human | Esophagus | ESCC | 6.81e-06 | 4.23e-01 | 0.0875 |
| 9212 | AIM1 | P2T-E | Human | Esophagus | ESCC | 9.49e-19 | 2.70e-01 | 0.1177 |
| 9212 | AIM1 | P4T-E | Human | Esophagus | ESCC | 4.75e-06 | 1.92e-01 | 0.1323 |
| 9212 | AIM1 | P5T-E | Human | Esophagus | ESCC | 1.31e-18 | 6.51e-02 | 0.1327 |
| 9212 | AIM1 | P8T-E | Human | Esophagus | ESCC | 3.82e-17 | 2.48e-01 | 0.0889 |
| 9212 | AIM1 | P9T-E | Human | Esophagus | ESCC | 9.50e-09 | 8.24e-03 | 0.1131 |
| 9212 | AIM1 | P10T-E | Human | Esophagus | ESCC | 9.85e-06 | -6.22e-02 | 0.116 |
| 9212 | AIM1 | P12T-E | Human | Esophagus | ESCC | 5.63e-11 | 1.53e-01 | 0.1122 |
| 9212 | AIM1 | P15T-E | Human | Esophagus | ESCC | 1.22e-08 | 2.04e-01 | 0.1149 |
| 9212 | AIM1 | P16T-E | Human | Esophagus | ESCC | 2.78e-18 | 3.74e-01 | 0.1153 |
| 9212 | AIM1 | P17T-E | Human | Esophagus | ESCC | 2.21e-05 | 3.09e-01 | 0.1278 |
| 9212 | AIM1 | P20T-E | Human | Esophagus | ESCC | 8.07e-13 | 2.69e-01 | 0.1124 |
| 9212 | AIM1 | P21T-E | Human | Esophagus | ESCC | 3.06e-39 | 8.85e-01 | 0.1617 |
| 9212 | AIM1 | P22T-E | Human | Esophagus | ESCC | 3.17e-04 | -3.24e-02 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AIM1 | SNV | Missense_Mutation | rs767966320 | c.4241N>A | p.Arg1414Gln | p.R1414Q | Q9Y4K1 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| AIM1 | SNV | Missense_Mutation | novel | c.5078N>T | p.Gly1693Val | p.G1693V | Q9Y4K1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| AIM1 | SNV | Missense_Mutation | rs753264982 | c.4656N>G | p.Ser1552Arg | p.S1552R | Q9Y4K1 | protein_coding | deleterious(0) | benign(0.062) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| AIM1 | SNV | Missense_Mutation | c.4287N>G | p.Ser1429Arg | p.S1429R | Q9Y4K1 | protein_coding | tolerated(0.18) | possibly_damaging(0.648) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| AIM1 | SNV | Missense_Mutation | c.3798N>C | p.Met1266Ile | p.M1266I | Q9Y4K1 | protein_coding | tolerated(0.74) | benign(0.017) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| AIM1 | SNV | Missense_Mutation | c.1240G>A | p.Asp414Asn | p.D414N | Q9Y4K1 | protein_coding | tolerated_low_confidence(0.43) | benign(0.003) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| AIM1 | SNV | Missense_Mutation | c.1562G>C | p.Gly521Ala | p.G521A | Q9Y4K1 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| AIM1 | SNV | Missense_Mutation | c.1492N>C | p.Glu498Gln | p.E498Q | Q9Y4K1 | protein_coding | tolerated_low_confidence(0.05) | benign(0.367) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| AIM1 | SNV | Missense_Mutation | novel | c.2320N>C | p.Asp774His | p.D774H | Q9Y4K1 | protein_coding | deleterious(0.02) | possibly_damaging(0.615) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| AIM1 | SNV | Missense_Mutation | novel | c.5095C>G | p.Gln1699Glu | p.Q1699E | Q9Y4K1 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |